This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): carbidopa/levodopa/entacapone
Description: Stalevo is a combination medication that adds Comtan (entacapone) to levodopa/carbidopa, which was introduced in 1970.
Levodopa is broken down by 3 separate enzymes: Dopa decarboxylase (DDC), Catecholamine-O-methyltransferase (COMT), and Monoamine oxidase B (MAO-B). DDC and COMT break down levodopa before it gets to the brain.
Carbidopa, which does not enter the brain, blocks DDC from converting levodopa to dopamine, allowing lower levels of levodopa to be used and reducing the nausea that results from dopamine formed in the stomach.
Comtan inhibits COMT, the most potent of the enzymes that break down levodopa, prolonging levodopa's duration of action and resulting in a less erratic and more continuous delivery of levodopa to the brain.
Deal Structure: Revenue splits for this drug are BioMedTracker estimates.
In September 2000, Novartis licensed Stalevo from Orion Pharma, which retained exclusive rights in certain Scandinavian/Baltic/Eastern European countries, the UK, Ireland, and Germany.
Historical drug revenue includes both Stalevo and Comtan.
Partners: Orion Corporation
Pink Sheet Novartis Stalevo approval in Parkinson’s
Pink Sheet Novartis/Orion Stalevo for Parkinson’s
Additional information available to subscribers only: